Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Bramow

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Plos One|May 18, 2021
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Mathias Due Buron, Volkert Siersma, et al.
Ugeskrift for Laeger|November 21, 2025
[Vaccination of individuals undergoing immunosuppressive therapy]Zitta Barrella Harboe, Peter Henrik Andersen, Peter Asdahl, et al.
Acta Neuropathologica|February 9, 2026
Characteristic patterns of complement deposition in NMOSD, MOGAD, and MSYoshiki Takai, Simon Hametner, Christian Riedl, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Plos One|May 18, 2021
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Mathias Due Buron, Volkert Siersma, et al.
Ugeskrift for Laeger|November 21, 2025
[Vaccination of individuals undergoing immunosuppressive therapy]Zitta Barrella Harboe, Peter Henrik Andersen, Peter Asdahl, et al.
Acta Neuropathologica|February 9, 2026
Characteristic patterns of complement deposition in NMOSD, MOGAD, and MSYoshiki Takai, Simon Hametner, Christian Riedl, et al.
CNS Drugs|September 18, 2021
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, et al.
Multiple Sclerosis and Related Disorders|June 11, 2021
The effectiveness of natalizumab vs fingolimod-A comparison of international registry studiesJohanna B Andersen, Sifat Sharmin, Mathilde Lefort, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|May 20, 2026
Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort studyIzanne Roos, Sifat Sharmin, Dana Horakova, et al.
Pageof 2